Keller Rohrback Investigates Potential Amputation Risk with Type 2 Diabetes Treatment Drugs Invokana, Invokamet, and Invokamet XR
May 31, 2017
Keller Rohrback L.L.P. is investigating the increased risk of leg and foot amputations (full or partial) when taking the SGLT2 inhibitors: Invokana, Invokamet, Invokamet XR, all of which are used for the treatment of Type 2 diabetes. The investigation follows a recent Safety Announcement made by the U.S. Food and Drug Administration (FDA) on May 16, 2017, which was made following the findings from two clinical studies that concluded that the Type 2 diabetes medicines Invokana, Invokamet and Invokamet XR causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, to be added to these drug labels to describe this risk. Researchers found that, over a year, twice as many patients given these medicines required amputations as those who took a placebo.
Invokana, Invokamet, and Invokamet XR are manufactured by Janssen Pharmaceuticals, Inc., a Johnson & Johnson (NYSE: JNJ) subsidiary. The FDA issued a similar Drug Safety Communication to Janssen Pharmaceuticals, Inc. a year ago on May 18, 2016, also warning that Type 2 diabetes medication Invokana could cause an increase in leg and foot amputations.
If you have taken Invokana, Invokamet, or Invokamet XR and have suffered from an amputation as a result, please contact attorney Michael Woerner or paralegal Katy Warner at (800) 776-6044 or email [email protected]. Keller Rohrback LLP, 1201 Third Ave., #3400, Seattle, WA 98101.
Attorney Advertising. Prior results do not guarantee a similar outcome. Not licensed to practice law in all states. Please refer to our website for details.
Contact Us:
